Related Experiment Video
Updated: May 24, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Evidence-based methylxanthine use in the NICU
1The Center for Research, Education, and Quality MEDNAX Services/Pediatrix Medical Group/American Anesthesiology, 1301 Concord Terrace, Sunrise, FL 33323, USA. alan_spitzer@pediatrix.com
Caffeine therapy is a highly effective and safe treatment for apnea of prematurity in the neonatal intensive care unit (NICU). This intervention offers significant benefits for premature infants, proving superior to other methylxanthines.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Respiratory Physiology
Background:
- Apnea of prematurity is a common challenge in neonatal intensive care.
- Methylxanthines, particularly caffeine, have emerged as a primary therapeutic agent.
Purpose of the Study:
- To evaluate the efficacy and safety of caffeine for treating apnea of prematurity.
- To compare caffeine with other methylxanthine treatments.
Main Methods:
- Review of clinical trials and evidence on methylxanthine use in neonates.
- Analysis of effectiveness in reducing apnea events and related complications.
Main Results:
- Caffeine demonstrates significant effectiveness in managing apnea of prematurity across diverse NICU populations.
- It is associated with reduced risks of bronchopulmonary dysplasia, patent ductus arteriosus, and reintubation.
- Caffeine presents a favorable safety profile with minimal short- and long-term risks.
Conclusions:
- Caffeine is the most effective and safest methylxanthine for treating apnea of prematurity.
- It is a cost-effective therapy with substantial clinical benefits for premature infants.
Related Concept Videos
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Pharmacokinetics in Pediatric Patients: Drug Excretion
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Drug Delivery: Enteral Route
Drugs in...
